GoodRx Holdings, Inc.
GoodRx Holdings, Inc. is classed by the SEC under Services-Computer Processing & Data Preparation (industry code 7374), based in Santa Monica, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $797 million and a profit of $30 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 7374, Services-Computer Processing & Data Preparation); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.7 out of ten, 9 of 9 metrics filed: past 5.2 out of ten, present 4.7 out of ten, future 4.2 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 2.7 out of ten. 2 warning events since 2020; the latest 2026-03-18. 27th percentile among 77 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 5.4 out of ten. +18% a year over 8 filed years; profitable in 4 of 8. 54th percentile among 64 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 8.5 out of ten. Share count shrank 4.7% a year. 98% of cash flow returned. Insiders: 2 sales, 0 purchases. 85th percentile among 44 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.1 out of ten. ROE 5%: 5¢ of profit per shareholder dollar. Leverage 56%: owes 56¢ per asset dollar. 61st percentile among 69 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 5.0 out of ten. bottom 50% of 68 in its family; net margin 3.8%. 50th percentile among 68 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 1.9 out of ten. bottom 19% of 37 in its family for leadership; chief executive since 2025. 19th percentile among 37 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.6 out of ten. bottom 46% of 68 in its family for room to expand. 46th percentile among 68 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 2.8 out of ten. bottom 28% of 64 in its family for growth drivers. 28th percentile among 64 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.7 out of ten. top 43% of 53 in its family for expectations against reality. 57th percentile among 53 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-26 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-09-15. Filings on record since 2020. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Prescription Transactions Revenue 68%, Pharma Direct Revenue 19%, Subscription Revenue 11%, Other Revenue 2%. As tagged in its annual report (Form 10-K, filed 2026-02-26).
Who runs it
Barnes, Wendy Lynn (Chief Executive Officer and President); Wagner, Scott (Interim Chief Executive Officer); Bezdek, Trevor (Chairman); Fengler, Justin (Chief Financial Officer and Chief Strategy & Operations Officer); Mcginnis, Christopher A (Chief Financial Officer & Treasurer); Chan, Thomas (tc) (Chief Accounting Officer); Hirsch, Douglas Joseph (Chief Mission Officer); Nabiey, Romin (Chief Accounting Officer); Bruehlman, Ronald E (director); Kennedy, Kelly J. (director); and 7 more. 17 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.